BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 1, 2025
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» PPMD funding supports Kinea’s AAV-mediated midi-dystrophin gene replacement therapy for DMD
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
PPMD funding supports Kinea’s AAV-mediated midi-dystrophin gene replacement therapy for DMD
Feb. 14, 2024
No Comments
Parents Project Muscular Dystrophy (PPMD) has provided $500,000 in funding to Kinea Bio Inc.
BioWorld Science
Gene therapy
Neurology/psychiatric
Grant
